Hong-Hong Yan

9PUBLICATIONS
41CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer diagnosisCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jan 13, 2026
Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS).

Anna Li, Wei-Neng Feng, Juan Li

|Jan 24, 2025
Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non-Small Cell Lung Cancer.

Jia-Tao Zhang, Si-Yang Liu, Xuan Gao

|Feb 09, 2024
Plasma ddPCR for the detection of <i>MET</i> amplification in advanced NSCLC patients: a comparative real-world study.

Jun-Wei Su, Cheng-Di Weng, Xiao-Cheng Lin

|Dec 06, 2023
Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study.

Si-Yang Liu, Song Dong, Xue-Ning Yang

|Apr 28, 2023
Circulating tumor cells dynamics during chemotherapy predict survival and response in advanced non-small-cell lung cancer patients.

Zhen Wang, Xu-Chao Zhang, Wei-Neng Feng

|Feb 23, 2023
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial.

Wen-Zhao Zhong, Hong-Hong Yan, Ke-Neng Chen

Pageof 2

Frequent Collaborators

6 joint publications

Yi-Long Wu

3 joint publications

Wen-Zhao Zhong

3 joint publications

Ying Cheng

3 joint publications

Xue-Ning Yang